Latest News

  • ‘Reverse Metabolomics’ Enables Biological Discoveries From Repository Data

    Diagnostics World | In a turnaround of the usual metabolomics study approach, University of California San Diego scientists are homing in on the microbial-produced molecules that interact with cells and affect human health. A couple million such molecules are likely awaiting discovery in this fashion.

    Jan 9, 2024
  • Top Stories from 2023: AI Prognostics, Illumina, CF Screening, exRNA Biology, More

    Diagnostics World | AI took center stage in diagnostics stories in 2023, assessing breast cancer prognoses and helping identify biomarkers. But it’s also under the microscope as researchers seek to validate “black box” AI findings. Plus: news from Illumina and a call for more diverse cystic fibrosis screening. Here’s a look at the top stories from Diagnostics World as well as thought leaders in the industry.

    Jan 4, 2024
  • Trendspotting: What’s Coming for Diagnostics in 2024

    Diagnostics World | To kick off the New Year, we spoke with leaders and experts in the Diagnostic World community about their insights and predictions for 2024.

    Jan 3, 2024
  • PerkinElmer Acquires Covaris, Revvity Launches New Platform, New Diagnostic Devices, Studies, More

    Diagnostics World | PerkinElmer has acquired Covaris; Revvity has launched its EONIS Q system, which can help test for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns; Edinburgh Innovations has announced a novel 3D printed device that could replace the need for drug and chemical safety testing on animals; and more.

    Dec 28, 2023
  • Follow the Money: PCORI Approves Awards For Multiple CER Studies, Small Molecule Therapies, “Google Maps” for Drug Discovery, More

    Diagnostics World | PCORI approves funding awards meant to fill evidence gaps related to multiple different illnesses; Apple Tree Partners will expand its portfolio company Deep Apple Therapeutics to rapidly discover novel small molecule therapeutics for high-value targets through virtual screening of AI-generated virtual libraries; Pepper Bio, the “Google Maps for drug discovery,” plans to accelerate its transomics platform capabilities, fueling the pipeline for more accurate and accessible drug discovery; and more.

    Dec 27, 2023
  • Epigenetic Biomarkers Needed For Shift From Treatment To Prevention

    Diagnostics World | There is mounting evidence that epigenetics—the molecular processes that influence how genes are expressed—is an equally if not more important driver of disease conditions and phenotypic differences than genetics. That means that accelerating the shift from reactionary medicine to preventive care is going to require biomarkers of these heritable and reversible changes.

    Dec 21, 2023
  • NIH Program Tackles Bottlenecks In ‘Wild West’ Field Of exRNA Biology

    Diagnostics World | A decade ago, the National Institutes of Health (NIH) launched a program designed to answer fundamental questions about extracellular RNA (exRNA), such as how it is used by cells and distant organs and if diseased and healthy cells produce different varieties of it. The program concludes at the end of this year but leaves science with technologies to address some of the biggest bottlenecks encountered by researchers in the niche field of study

    Dec 19, 2023
  • Illumina to Divest GRAIL Business by Q2 2024

    Diagnostics World | On Sunday, Illumina announced that the company will divest GRAIL.

    Dec 17, 2023
  • Novel DNA Methylation Markers, Biosensor Aim for Early Detection of Cervical Cancer

    Diagnostics World |An international research consortium led by scientists from LMU University Hospital Munich has tested a new simple, rapid tuberculosis test that uses a blood sample from the fingertip. The candidate test, called the Cepheid Mycobacterium tuberculosis Host Response prototype cartridge (MTB-HR), works by measuring a three-gene transcriptomic signature.

    Dec 14, 2023
  • Living Biobank Of Brain Metastasis Samples Enabling ‘Personalized Medicine 2.0’

    Diagnostics World |Researchers at the CNIO (Spanish National Cancer Research Centre) are forwarding the idea that metastasis, rather than the primary tumor, should be the focus of cancer treatment, which would both further the cause of personalized medicine and generate biomarkers of sensitivity or resistance to specific drugs.

    Dec 13, 2023
  • Finger Prick Test Aims to Simplify Childhood Tuberculosis Diagnosis

    Diagnostics World |An international research consortium led by scientists from LMU University Hospital Munich has tested a new simple, rapid tuberculosis test that uses a blood sample from the fingertip. The candidate test, called the Cepheid Mycobacterium tuberculosis Host Response prototype cartridge (MTB-HR), works by measuring a three-gene transcriptomic signature.

    Dec 12, 2023
  • Prognostic Biomarker Scores Big For High-Risk Breast Cancer Cases

    Diagnostics World | Cytovale will bring its rapid sepsis diagnosis test to more hospital emergency departments (ED) and health systems in the United States; Elucid intends to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease; Flashpoint Therapeutics to advance its programs on Oncology, Peptide Therapeutics, and CRISPR; more.

    Dec 7, 2023
  • Researchers In Japan Identify High-Potential Biomarker Of Gastric Cancer

    Diagnostics World | Cytovale will bring its rapid sepsis diagnosis test to more hospital emergency departments (ED) and health systems in the United States; Elucid intends to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease; Flashpoint Therapeutics to advance its programs on Oncology, Peptide Therapeutics, and CRISPR; more.

    Dec 5, 2023
  • Follow the Money: Sepsis Diagnostic Test, Expanding Cardiovascular Disease Info, Oncology, Peptide Therapeutics, CRISPR

    Diagnostics World | Cytovale will bring its rapid sepsis diagnosis test to more hospital emergency departments (ED) and health systems in the United States; Elucid intends to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease; Flashpoint Therapeutics to advance its programs on Oncology, Peptide Therapeutics, and CRISPR; more.

    Nov 30, 2023
  • Illumina Partners With Veracyte; Boston Scientific Corporation Acquires Relievant Medsystems; Oxford Nanopore Collaborates With Fabric Genomics

    Diagnostics World | Illumina enters a multi-year agreement with Veracyte to develop and offer some of its high-performing molecular tests as decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx next-generation sequencing (NGS) instrument; Boston Scientific Corporation acquires Relievant Medsystems to add to chronic pain portfolio; Oxford Nanopore Technologies and Fabric Genomics collaborate to develop a software solution analysis and clinical reporting of rich genomic data for faster insights to support rapid disease characterization of babies and children with genetic disorders in acute settings; more.

    Nov 29, 2023
  • AI-Based Platform For Detecting AFib Put To The Test In VA Facilities

    Diagnostics World | Investigators at Cedars-Sinai Medical Center are looking to minimize the biases in the data used by artificial intelligence (AI) algorithms, most recently a deep learning model trained on nearly a million electrocardiograms (ECGs) to identify people with abnormal heart rhythms.

    Nov 28, 2023
  • For Equitable CF Screening, We Should Expand Our Definition of Pathogenic Variants

    Diagnostics World | Cystic fibrosis (CF) is one of the few genetic disorders to be considered both serious and common enough to merit universal carrier or prenatal screening. Unfortunately, though, current testing approaches are caught between evolution and revolution even as they continue to produce suboptimal results for people of non-European ancestry.

    Nov 21, 2023
  • Illumina Releases Updated TruSight Oncology Liquid Biopsy Assay

    Diagnostics World | Illumina announced a new generation of its distributed liquid biopsy assay for genomic profiling. The new TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that enables noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not available, or to complement tissue-based testing.

    Nov 16, 2023
  • The Last Mile In Preventing A Deadly Hospital Infection

    Diagnostics World | The “power of the team approach” was on full display for a study designed to understand the contribution of asymptomatic carriers to the spread of Clostridioides difficile in hospitals.

    Nov 15, 2023
  • Illumina Launches Program to Discount Pathogen Sequencing Tools for Public Health

    Bio-IT World | Illumina has launched the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs) and reduced prices.

    Nov 13, 2023